Your Ultimate FTSE 100 4-Stock Balanced Portfolio: SSE PLC, AstraZeneca plc, Banco Santander SA & Unilever plc

SSE PLC (LON:SSE), AstraZeneca plc (LON:AZN), Banco Santander SA (LON:BNC) and Unilever plc (LON:ULVR) provide a potent mix of income and capital growth potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

city

Sometimes it’s tough to strike the right balance between growth and income. Indeed, most investors tend to focus on one or the other, as opposed to creating a portfolio that provides them with a decent income while also having the potential to post impressive capital gains.

With that in mind, here are four stocks that, together, offer impressive dividends as well as exciting future prospects.

SSE

As far as income plays go, few stocks in the FTSE 100 can match SSE (LSE: SSE). That’s because it currently yields a hugely impressive 6% and, better still, dividends per share are all set to rise by at least the inflation rate over the medium term.

This may not sound like such an appealing option when inflation is less than 2%. However, with the scale of quantitative easing having the potential to push the inflation rate much higher over the medium term, SSE’s planned dividend increases could become a real asset. Indeed, they could help to maintain your income levels in real terms moving forward.

AstraZeneca

While also offering a respectable yield of 3.6%, AstraZeneca (LSE: AZN) comes with huge capital growth potential. That’s because its drugs pipeline is undergoing nothing short of a transformation right now.

Certainly, the company’s bottom line is due to be hit by continued fallout from the current patent cliff, with earnings forecast to fall by 13% this year and by 6% next year. However, looking beyond that, numerous acquisitions have made AstraZeneca’s pipeline a hot ticket. Indeed, further bids from global rivals are a very real possibility, which would clearly be good news for shareholders.

Banco Santander

Few companies offer the potent mix of income and growth that Santander (LSE: BNC) does. It currently yields a whopping 7.4% and offers huge growth potential. For instance, earnings per share (EPS) are due to increase by 23% in the current year and by 21% next year. This is well ahead of the market average and shows that Santander is a true growth play.

Of course, investors are being asked to pay a premium for such strong growth potential, with shares in Santander currently trading on a price to earnings (P/E) ratio of 15.6. This is much higher than the FTSE 100’s P/E of 13.8. However, when Santander’s growth forecasts are taken into account, it equates to a price to earnings growth (PEG) ratio of just 0.6, which shows that for the level of growth on offer, Santander trades at a reasonable price.

Unilever

With a yield of 3.3% and forecast growth in earnings of 9% next year, Unilever (LSE: ULVR) seems to strike the right balance between growth and income. Indeed, the consumer goods play seems to have a very bright future ahead of it.

For instance, customer loyalty in its brands is constantly increasing in the developing world, where Unilever has invested vast amounts of time and money to ensure the long term growth of its products. This exposure (emerging markets account for over half of Unilever’s revenue) could prove to be highly beneficial for investors moving forward, as greater wealth and consumer spending are anticipated across the developing world. As a result, shares in the company could deliver impressive gains over the medium term.

Peter Stephens owns shares of AstraZeneca and SSE. The Motley Fool UK owns shares of Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Happy young female stock-picker in a cafe
Investing Articles

1 top investment trust to consider from the FTSE 250 

This niche FTSE 250 investment trust offers exposure to one of Asia's fastest growing economies, potentially setting it up for…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

2 high risk/high reward stock market picks to consider in 2026

The coming year could bring about lots of stock market opportunities for brave investors willing to stomach risk. Mark Hartley…

Read more »

Investing Articles

ChatGPT thinks these are the 5 best FTSE stocks to consider buying for 2026!

Can the AI bot come up trumps when asked to select the best FTSE stocks to buy as we enter…

Read more »

Investing For Beginners

How much do you need in an ISA to make the average UK salary in passive income?

Jon Smith runs through how an ISA can help to yield substantial income for a patient long-term investor, and includes…

Read more »

Investing Articles

3 FTSE 250 shares to consider for income, growth, and value in 2026!

As the dawn of a new year in the stock market approaches, our writer eyes a trio of FTSE 250…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Want to be a hit in the stock market? Here are 3 things super-successful investors do

Dreaming of strong performance when investing in the stock market? Christopher Ruane shares a trio of approaches used by some…

Read more »

Two white male workmen working on site at an oil rig
Investing Articles

The BP share price has been on a roller coaster, but where will it go next?

Analysts remain upbeat about 2026 prospects for the BP share price, even as an oil glut threatens and the price…

Read more »

Investing Articles

Prediction: move over Rolls-Royce, the BAE share price could climb another 45% in 2026

The BAE Systems share price has had a cracking run in 2025, but might the optimism be starting to slip…

Read more »